The beneficial effects were associated with reduction of lysine acetylation in 14-3-3β and augmentation of interaction between 14-3-3β and synaptopodin, further extending the clinical potential of Resolvins in the treatment of chronic kidney diseases. This evidence concerns the gene SYNPO and chronic kidney disease.